PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents growing 32.15% while CRVO's declined -48.60%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Below half of CRVO's -48.60%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Below half of CRVO's -51.20%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.88%
Below half CRVO's -6.80%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half of CRVO's 0.76%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Below half of CRVO's -8.20%. Michael Burry sees a potential red flag for stagnation or capital shortage.
63.16%
50-75% of CRVO's 122.34%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Less than half of CRVO's 82.84%. David Dodd sees fewer expansions in other current obligations.
49.30%
Above 1.5x CRVO's 20.57%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Above 1.5x CRVO's 9.78%. Michael Burry sees a potential leverage warning sign.
16.87%
Higher Common Stock (Book Value) Growth compared to CRVO's zero value, indicating worse performance.
-5.16%
1.25-1.5x CRVO's -4.46%. Bruce Berkowitz notes stronger reinvestment strategy.
-13.18%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half CRVO's -20.04%. Michael Burry sees potential underperformance in building shareholder capital.
30.51%
Below half CRVO's -8.20%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Less than half of CRVO's 248.32%. David Dodd sees better deleveraging or stronger cash buildup than competitor.